Skip to content

A Split-face, Evaluator-blinded, Randomized Controlled Trial Study Comparing Efficacy between Low-fluence Alexandrite 755-nm Picosecond Laser and low-fluence Neodymium-doped yttrium Aluminum Garnet (Nd:YAG) 1064-nm Picosecond for the Treatment Of Mixed Type Melasma in Asians

A Split-face, Evaluator-blinded, Randomized Controlled Trial Study Comparing Efficacy between Low-fluence Alexandrite 755-nm Picosecond Laser and low-fluence Neodymium-doped yttrium Aluminum Garnet (Nd:YAG) 1064-nm Picosecond for the Treatment Of Mixed Type Melasma in Asians

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220405004
Enrollment
22
Registered
2022-04-05
Start date
2020-04-28
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heathy person Chloasma, Facial hyperpigmentation, Pigmentary disorder, Postinflammatory hyperpigmentation

Interventions

One side was randomly treated with alexandrite 755-nm picosecond laser ,One side was randomly treated with Nd:YAG 1064-nm picosecond laser
Experimental Device,Active Comparator Device
alexandrite 755-nm picosecond laser ,Nd:YAG 1064-nm picosecond laser

Sponsors

Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Healthy subjects older than 18-year-old

Exclusion criteria

Exclusion criteria: The exclusion criteria were as follows: (i) severe medical conditions, (ii) other skin diseases on the face, (iii) immunocompromised status, (iv) history of skin cancer or keloids, (v) history of recurrent herpes infection, (vi) coagulopathy, (vii) history of laser/light therapy or other facial procedures at cheek within 2 months prior to the study, (viii) history of chemical peeling for melasma within 2 months prior to the study, (ix) history of topical treatment for melasma within 1 month prior to the study, and/or (x) pregnant or lactation

Design outcomes

Primary

MeasureTime frame
Relative lightness index 4 and 8 weeks after completing the 5th treatment sessions colorimeter

Secondary

MeasureTime frame
Melasma Area and Severity Index (MASI) 4 and 8 weeks after completing the 5th treatment sessions physician (blinded)

Countries

Thailand

Contacts

Public ContactVasanop Vachiramon

Faculty of Medicine, Ramathibodi hospital

vasanop@gmail.com0946369165

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026